Fibrocell Science Email Format

Biotechnology ResearchPennsylvania, United States11-50 Employees

Fibrocell Science is a biotechnology research company developing cell and gene therapies for rare skin and connective tissue diseases. It uses its autologous fibroblast platform to create personalized biologics aimed at addressing the root causes of disease. The company's development pipeline includes FCX-007 for recessive dystrophic epidermolysis bullosa, a severe inherited condition diagnosed in infancy with no approved cures, and FCX-013 for moderate to severe localized scleroderma. Both programs focus on localized delivery to affected tissues. 

Based in Exton, Pennsylvania, Fibrocell operates in the biotechnology research sector, targeting patients with rare conditions who have limited treatment options. The company has pursued collaborations to advance its lead programs, including a 2019 agreement with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 for RDEB.

Sign up for free to view info

Company overview Employee directory